Ryvu Therapeutics is advancing a broad pipeline by addressing emerging targets in oncology.

Our pipeline includes candidates with differentiated therapeutic mechanisms, including programs directed at kinase, synthetic lethality, and immuno-oncology pathways.

Clinical Projects

  • Program/ Target Name
  • Indication
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Partner
  • Anticipated
    Milestones
  • RVU120
    CDK8/19
    • AML/MDS
    • Complete Phase I &
      Initiate Phase II in H2 2023

    • SOLID TUMORS
    • Data at ESMO 2023;
      Initiate Phase II in H2 2023

  • SEL24 (MEN1703)
    PIM/FLT3
    • DLBCL

Discovery & Preclinical Projects

  • Program/ Target Name
  • Indication
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Partner
  • Anticipated
    Milestones

Synthetic Lethality

  • PRMT5
    • Solid tumors
    • Development candidate
      in 2023

  • WRN
    • Solid tumors
    • In vivo¬†POC
      in 2023

  • NOVEL TARGETS
    • ONCOLOGY

Immuno-oncology

  • STING Standalone
    • Solid tumors
  • STING ADC
    • ONCOLOGY
  • HPK1
    • Solid tumors

 

  • Immune Modulation Research Collaboration (Multi-Target)

 

  • Discovery Collaboration